摘要
目的:以利培酮为对照,探讨齐拉西酮治疗精神分裂症的疗效和安全性。方法:将70例符合CCMD一3诊断标准的精神分裂症病人随机分为两组,分别给予齐拉西酮和利培酮治疗8周。于治疗前和治疗后2、4、8周末采用阳性症状和阴性症状量表(PANSS)评定临床疗效,副反应量表(TESS)评定副反应。结果:治疗8周后,两组疗效近似(P>0.05),齐拉西酮组和利培酮组的有效率差异无显著性(P>0.05);齐拉西酮组的副反应发生率低于利培酮组,但差异无显著性(P>0.05)。利培酮组锥体外系副反应明显高于齐拉西酮组(P<0.05)。结论:齐拉西酮对精神分裂症患者的疗效与利培酮相当,副作用较小。
Objective： To investigate the clinical efficacy and side effects of zipraside with risperidone as a control in the treatment of schizophrenia.Methods：A tota1 of 70 cases meeting the criteria of CCM D-3 for schizophrenia were randomly assigned to two group treated with zipraside（zipraside group） or risperidone（risperidone group）for 8 weeks.The positive and negative symptoms scale（PANSS）and treatment emergent symptoms scale（TESS）were used to evaluate the efficacy and adverse effects before treatment and at the end of 2-,4-and 8-week treatment.Results：The therapeutic efficacy in zipraside group was similar to that in risperidone group（P0.05）,with no significant difference between the two groups（P0.05）.The incidence of adverse effects in zipraside group was lower than that in risperidone group,with no significant difference between the two groups（P0.05）,The incidence of extrapyramidal symptoms in risperidone group was significantly higher than that in zipraside group.Conclusion：Zipraside is as effective as risperidone in the treatment of schizophrenia with fewer side effects.
出处
《黑龙江医药科学》
2011年第5期18-19,共2页
Heilongjiang Medicine and Pharmacy
关键词
齐拉西酮
利培酮
精神分裂症
疗效
zipraside
risperidone
schizophrenia
curative effect
